论文部分内容阅读
目的观察阿卡波糖对糖耐量减低患者干预的临床疗效。方法 50名IGT患者随机分成2组,对照组25名,经糖尿病饮食和运动治疗(3次/d,每次餐后20min,步行1.5～2.0km),治疗组25名,在与对照组相同的糖尿病饮食和运动治疗的基础上,给予阿卡波糖,50mg,日3次,餐时嚼服,每3个月行OGTT试验、检测空腹血糖(FPG)、2h血糖(OGTT2hPG)、糖化血红蛋白(HbA1c),以及血清胰岛素水平,观察9个月。结果治疗组患者FPG、OGTT2hPG血糖、HbA1c下降更明显;治疗组转为糖尿病患者为0例,对照组为1例,两组患者比较差异有统计学意义(P<0.05)。结论阿卡波糖可有效的干预糖耐量减低患者发展为临床糖尿病。
Objective To observe the clinical effect of acarbose on patients with impaired glucose tolerance. Methods Fifty IGT patients were randomly divided into two groups: control group (n = 25), diabetic diet and exercise therapy (n = 20) (OGTT2hPG), glycosylated hemoglobin (HbA1c) and HbA1c (HbA1c) were measured by OGTT test every 3 months on the basis of diet and exercise therapy. (HbA1c), and serum insulin levels, observed for 9 months. Results The FPG and OGTT2hPG blood glucose and HbA1c in the treatment group decreased more obviously. The treatment group was changed to diabetic patients in 0 cases and control group in 1 case. The difference between the two groups was statistically significant (P <0.05). Conclusion Acarbose can effectively interfere with the development of patients with impaired glucose tolerance for clinical diabetes.